Hepion Pharmaceuticals Finalizes Asset Sale of Rencofilstat to Panetta Partners with Contingent Value Rights for Shareholders
Hepion Pharmaceuticals Inc., a Delaware-based corporation, has announced an agreement with Panetta Partners Limited concerning the acquisition of all patent assets, knowhow, clinical trial data, and drug product related to Rencofilstat (formerly CRV431). Under the terms of the agreement, Panetta will provide a contingent value right to Hepion's stockholders, allowing them to receive contingent payments upon achieving specific milestones. These milestones include a $500,000 payment upon FDA approval of the first new drug application for Rencofilstat, a $1,000,000 payment when net sales of an approved drug product containing Rencofilstat exceed $350,000,000, and a $3,000,000 payment when net sales surpass $750,000,000. The transaction was announced by Hepion Pharmaceuticals Inc. on May 26, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013048), on May 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.